Mersana Therapeutics, a biopharmaceutical company developing its Fleximer antibody-drug conjugate (ADC) platform and therapeutics, has announced two executive appointments. In a release, the Company noted: Donald A. Bergstrom , M.D., Ph.D., has been appointed Chief Medical Officer, adding substantial experience in oncology translational research to Mersana's team. Eva M. Jack has been appointed Mersana's Chief Business Officer, bringing a successful track record in business development and venture capital. David Mott , chairman of the company's Board of Directors, was also recently named Executive Chairman, following Nicholas Bacopoulos' return to his Board of Directors' role after having stepped in as CEO to lead the company through a transition over the past few years. "Don is an extraordinary oncology translational scientist and drug developer," said David Mott , Executive Chairman of Mersana. "He joins us at an exciting time in the maturation of our technology. He will be instrumental both in helping us select the best therapeutics for internal development and in enhancing our collaborations with partners as we apply our technology to their therapeutics candidates. His experiences at Sanofi and Merck as well as in academic medicine will be invaluable as we continue to progress at Mersana." "Eva is a seasoned business development executive and operational leader with whom I have had the pleasure of working in the past; we are fortunate to now welcome her to Mersana," continued Mott. "Her prior experiences at MedImmune and Pulmatrix, as well her consulting work in the industry, position her well to advance Mersana's corporate development efforts, working to strike important collaborations and alliances as we build a next-generation ADC company." Mott also said, "We are grateful to Nick Bacopoulos for having stepped in from the board three years ago to lead the company through a repositioning to focus its technology exclusively on the ADC field and within oncology. We are in a stronger place today as a result of Nick's leadership, and we look forward to his continued contributions on our Board of Directors." Dr. Bergstrom joins Mersana after serving since May 2010 as Global Head of Translational and Experimental Medicine at Sanofi Oncology, where he led a team of more than 60 laboratory and clinical scientists who integrated translational science into oncology drug development. From 2004 to 2010, Dr. Bergstrom held roles of increasing responsibility at Merck Research Laboratories , culminating in his role as Oncology Franchise Lead, Experimental Medicine. Prior roles at Merck included positions in Oncology Clinical Research and Clinical Molecular Profiling. Dr. Bergstrom received an M.D. from the University of Washington, Seattle and a Ph.D. from the Fred Hutchinson Cancer Research Center , where he also completed post-doctoral training. He was a resident in clinical pathology at the University of Washington . Jack joins Mersana after serving as an independent advisor and consultant to biotech companies and investors on business and financing strategies since 2012. From 2010 to 2012, she served as the Chief Business Officer of Pulmatrix, and before that, she was with MedImmune , the worldwide biologics unit of AstraZeneca . Her most recent role within MedImmune was as Managing Director of MedImmune Ventures , and previously she worked in MedImmune's Business Development group, where she was responsible for in- licensing and out-licensing activities. Prior to joining MedImmune in 2004, Jack held a variety of positions at Intel Corp. , where she worked in venture investments, corporate strategy and public policy. ((Comments on this story may be sent to email@example.com ))
Most Popular Stories
- Obama Administration Releases Proposal to Regulate For-Profit Colleges
- Apple, HP, Intel May Take a Hit from Slowdown in Smartphone Sales Growth
- Elizabeth Vargas' Husband Marc Cohn Addresses Rumors
- FDIC Files Lawsuit on Behalf of Banks Allegedly Hurt by Libor Scandal
- Keurig Adds Peet's coffee, Alters Starbucks deal
- Motley Crue's Nikki Sixx Marries Model Courtney Bingham
- U.S. to Relinquish Gov't Control Over Internet
- Chinese e-Commerce Giant Alibaba Gears for IPO in U.S.
- Some California Cities Seeking Water Independence
- Will Missing Malaysian Jet Prompt Aviation System Change?